PilotHealth
Chemotherapy-free regimen shows promise in metastatic breast cancer
The ASPIRE phase 1/2 trial tested four targeted drugs in 29 previously untreated patients.
Written by AI1 source2 min
Loading…
Diagnostics, prosthetics, vaccines, genomics: the medicine that adds years to a life.
The ASPIRE phase 1/2 trial tested four targeted drugs in 29 previously untreated patients.
Washington University researchers developed NGSE-Corr to compare imaging tools when the true measurement is unknown.
Risca's team tracked liposarcoma and ER-positive breast cancer cells for nearly a month.
A six-month UIC trial assigned 32 adults to time-restricted eating, calorie reduction or no dietary change.
Sanford Burnham Prebys researchers identified Firefox and Honeybadger as opposing regulators of MYC-driven tumors.
Researchers at Birmingham and UCL compared 82 ultrasound detectors used in photoacoustic imaging.
A three-week program helped patients retain everyday abilities better than usual unstructured rehabilitation.
Yonsei researchers analyzed oral microbes from 507 volunteers, including people with gastric and colorectal cancer.
ASU researchers studied 8,687 blood samples from 4,089 people across healthy and immunosuppressed groups.
Monash University developed living kidney organoids that reproduce key features of human acute kidney injury.
The trial covered 20 Colombian urban areas, each with around 1,600 to 2,000 households.
The combination outperformed either treatment alone in a preclinical female-rodent model.
It targets BCL6, which normally silences genes that can stop growth or trigger programmed cell death.
An Australian team screened 63 existing medicines in patient-derived brain cells.
The University of Surrey study identified three distinct five-year health trajectories among 12,701 UK heart-attack survivors.
Risk was about 2% with one worrisome feature, 4% with two and 18% with three or more.
Vitestro’s Aletta can handle a blood draw while one trained phlebotomist oversees up to three devices.
Mayo Clinic researchers tested the model in 275 patients and validated it in 46 patients in South Korea.